Ramiro Garzon, MD

Journal Article

1. Mirza I, Garzón R, Burns J, Edwards L, Fernandez-Cymering C, Kloss (2001). Myelodysplastic syndromes: a community hospital-based study of prognostic factors and International Prognostic Scoring System. Connecticut medicine, 65(8), 455-63. (Read full publication)
2. Garzon R, Murphy J (2002). Acute bulbar muscle dysfunction in hyperthyroidism. Connecticut medicine, 66(1), 3-6. (Read full publication)
3. Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE, Iorio MV, Visone R, Sever NI, Fabbri M, Iuliano R, Palumbo T, Pichiorri F, Roldo C, Garzon R, Sevignani C, Rassenti L, Alder H, Volinia S, Liu CG, Kipps TJ, Negrini M, Croce C (2005). A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. The New England journal of medicine, 353(17), 1793-801. (Read full publication)
4. Garzon R, Pichiorri F, Palumbo T, Iuliano R, Cimmino A, Aqeilan R, Volinia S, Bhatt D, Alder H, Marcucci G, Calin GA, Liu CG, Bloomfield CD, Andreeff M, Croce C (2006). MicroRNA fingerprints during human megakaryocytopoiesis. Proceedings of the National Academy of Sciences of the United States of America, 103(13), 5078-83. (Read full publication)
5. Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E, Liu S, Alder H, Costinean S, Fernandez-Cymering C, Volinia S, Guler G, Morrison CD, Chan KK, Marcucci G, Calin GA, Huebner K, Croce C (2007). MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proceedings of the National Academy of Sciences of the United States of America, 104(40), 15805-10. (Read full publication)
6. Garzon R, Pichiorri F, Palumbo T, Visentini M, Aqeilan R, Cimmino A, Wang H, Sun H, Volinia S, Alder H, Calin GA, Liu CG, Andreeff M, Croce C (2007). MicroRNA gene expression during retinoic acid-induced differentiation of human acute promyelocytic leukemia. Oncogene, 26(28), 4148-57. (Read full publication)
7. Kulshreshtha R, Ferracin M, Wojcik SE, Garzon R, Alder H, Agosto-Perez FJ, Davuluri R, Liu CG, Croce CM, Negrini M, Calin GA, Ivan (2007). A microRNA signature of hypoxia. Molecular and cellular biology, 27(5), 1859-67. (Read full publication)
8. Hamadani M, Benson DM Jr, Blum W, Garzon R, Devine S (2008). Pulmonary Nocardia and Aspergillus co-infection in a patient with chronic graft-versus-host disease. Transplant infectious disease, 10(1), 24-6. (Read full publication)
9. Liu S, Liu Z, Xie Z, Pang J, Yu J, Lehmann E, Huynh L, Vukosavljevic T, Takeki M, Klisovic RB, Baiocchi RA, Blum W, Porcu P, Garzon R, Byrd JC, Perrotti D, Caligiuri MA, Chan KK, Wu LC, Marcucci (2008). Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemia. Blood, 111(4), 2364-73. (Read full publication)
10. Garzon R, Garofalo M, Martelli MP, Briesewitz R, Wang L, Fernandez-Cymering C, Volinia S, Liu CG, Schnittger S, Haferlach T, Liso A, Diverio D, Mancini M, Meloni G, Foa R, Martelli MF, Mecucci C, Croce CM, Falini (2008). Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proceedings of the National Academy of Sciences of the United States of America, 105(10), 3945-50. (Read full publication)
11. Garzon R, Volinia S, Liu CG, Fernandez-Cymering C, Palumbo T, Pichiorri F, Fabbri M, Coombes K, Alder H, Nakamura T, Flomenberg N, Marcucci G, Calin GA, Kornblau SM, Kantarjian H, Bloomfield CD, Andreeff M, Croce C (2008). MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood, 111(6), 3183-9. (Read full publication)
12. Calin GA, Cimmino A, Fabbri M, Ferracin M, Wojcik SE, Shimizu M, Taccioli C, Zanesi N, Garzon R, Aqeilan RI, Alder H, Volinia S, Rassenti L, Liu X, Liu CG, Kipps TJ, Negrini M, Croce C (2008). MiR-15a and miR-16-1 cluster functions in human leukemia. Proceedings of the National Academy of Sciences of the United States of America, 105(13), 5166-71. (Read full publication)
13. Marcucci G, Radmacher MD, Maharry K, Mrózek K, Ruppert AS, Paschka P, Vukosavljevic T, Whitman SP, Baldus CD, Langer C, Liu CG, Carroll AJ, Powell BL, Garzon R, Croce CM, Kolitz JE, Caligiuri MA, Larson RA, Bloomfield C (2008). MicroRNA expression in cytogenetically normal acute myeloid leukemia. The New England journal of medicine, 358(18), 1919-28. (Read full publication)
14. Pichiorri F, Suh SS, Ladetto M, Kuehl M, Palumbo T, Drandi D, Taccioli C, Zanesi N, Alder H, Hagan JP, Munker R, Volinia S, Boccadoro M, Garzon R, Palumbo A, Aqeilan RI, Croce C (2008). MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proceedings of the National Academy of Sciences of the United States of America, 105(35), 12885-90. (Read full publication)
15. Wang H, Garzon R, Sun H, Ladner KJ, Singh R, Dahlman J, Cheng A, Hall BM, Qualman SJ, Chandler DS, Croce CM, Guttridge D (2008). NF-kappaB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma. Cancer cell, 14(5), 369-81. (Read full publication)
16. Hamadani M, Benson DM Jr, Hofmeister CC, Elder P, Blum W, Porcu P, Garzon R, Blum KA, Lin TS, Marcucci G, Devine S (2009). Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-hodgkin lymphomas. Biology of blood and marrow transplantation, 15(5), 547-53. (Read full publication)
17. Garzon R, Liu S, Fabbri M, Liu Z, Heaphy CE, Callegari E, Schwind S, Pang J, Yu J, Muthusamy N, Havelange V, Volinia S, Blum W, Rush LJ, Perrotti D, Andreeff M, Bloomfield CD, Byrd JC, Chan K, Wu LC, Croce CM, Marcucci (2009). MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood, 113(25), 6411-8. (Read full publication)
18. Li Z, Hassan MQ, Jafferji M, Aqeilan RI, Garzon R, Croce CM, van Wijnen AJ, Stein JL, Stein GS, Lian J (2009). Biological functions of miR-29b contribute to positive regulation of osteoblast differentiation. The Journal of biological chemistry, 284(23), 15676-84. (Read full publication)
19. Hamadani M, Blum W, Phillips G, Elder P, Andritsos L, Hofmeister C, O'Donnell L, Klisovic R, Penza S, Garzon R, Krugh D, Lin T, Bechtel T, Benson DM, Byrd JC, Marcucci G, Devine S (2009). Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies. Biology of blood and marrow transplantation, 15(11), 1422-30. (Read full publication)
20. Garzon R, Heaphy CE, Havelange V, Fabbri M, Volinia S, Tsao T, Zanesi N, Kornblau SM, Marcucci G, Calin GA, Andreeff M, Croce C (2009). MicroRNA 29b functions in acute myeloid leukemia. Blood, 114(26), 5331-41. (Read full publication)
21. Liu S, Wu LC, Pang J, Santhanam R, Schwind S, Wu YZ, Hickey CJ, Yu J, Becker H, Maharry K, Radmacher MD, Li C, Whitman SP, Mishra A, Stauffer N, Eiring AM, Briesewitz R, Baiocchi RA, Chan KK, Paschka P, Caligiuri MA, Byrd JC, Croce CM, Bloomfield CD, Perrotti D, Garzon R, Marcucci (2010). Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia. Cancer cell, 17(4), 333-47. (Read full publication)
22. Eiring AM, Harb JG, Neviani P, Garton C, Oaks JJ, Spizzo R, Liu S, Schwind S, Santhanam R, Hickey CJ, Becker H, Chandler JC, Andino R, Cortes J, Hokland P, Huettner CS, Bhatia R, Roy DC, Liebhaber SA, Caligiuri MA, Marcucci G, Garzon R, Croce CM, Calin GA, Perrotti (2010). miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts. Cell, 140(5), 652-65. (Read full publication)
23. Blum W, Garzon R, Klisovic RB, Schwind S, Walker A, Geyer S, Liu S, Havelange V, Becker H, Schaaf L, Mickle J, Devine H, Kefauver C, Devine SM, Chan KK, Heerema NA, Bloomfield CD, Grever MR, Byrd JC, Villalona-Calero M, Croce CM, Marcucci (2010). Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proceedings of the National Academy of Sciences of the United States of America, 107(16), 7473-8. (Read full publication)
24. Volinia S, Galasso M, Costinean S, Tagliavini L, Gamberoni G, Drusco A, Marchesini J, Mascellani N, Sana ME, Abu Jarour R, Desponts C, Teitell M, Baffa R, Aqeilan R, Iorio MV, Taccioli C, Garzon R, Di Leva G, Fabbri M, Catozzi M, Previati M, Ambs S, Palumbo T, Garofalo M, Veronese A, Bottoni A, Gasparini P, Harris CC, Visone R, Pekarsky Y, de la Chapelle A, Bloomston M, Dillhoff M, Rassenti LZ, Kipps TJ, Huebner K, Pichiorri F, Lenze D, Cairo S, Buendia MA, Pineau P, Dejean A, Zanesi N, Rossi S, Calin GA, Liu CG, Palatini J, Negrini M, Vecchione A, Rosenberg A, Croce C (2010). Reprogramming of miRNA networks in cancer and leukemia. Genome research, 20(5), 589-99. (Read full publication)
25. Blum W, Klisovic RB, Becker H, Yang X, Rozewski DM, Phelps MA, Garzon R, Walker A, Chandler JC, Whitman SP, Curfman J, Liu S, Schaaf L, Mickle J, Kefauver C, Devine SM, Grever MR, Marcucci G, Byrd J (2010). Dose escalation of lenalidomide in relapsed or refractory acute leukemias. Journal of clinical oncology, 28(33), 4919-25. (Read full publication)
26. Chan KK, Liu Z, Xie Z, Chiu M, Wang H, Chen P, Dunkerson S, Chiu M, Liu S, Triantafillou G, Garzon R, Croce CM, Byrd JC, Muthusamy N, Marcucci (2010). A novel ultrasensitive hybridization-based ELISA method for 2-methoxyphosphorothiolate microRNAs and its in vitro and in vivo application. The AAPS journal, 12(4), 556-68. (Read full publication)
27. Schwind S, Maharry K, Radmacher MD, Mrózek K, Holland KB, Margeson D, Whitman SP, Hickey C, Becker H, Metzeler KH, Paschka P, Baldus CD, Liu S, Garzon R, Powell BL, Kolitz JE, Carroll AJ, Caligiuri MA, Larson RA, Marcucci G, Bloomfield C (2010). Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Journal of clinical oncology, 28(36), 5257-64. (Read full publication)
28. Hamadani M, Craig M, Phillips GS, Abraham J, Tse W, Cumpston A, Gibson L, Remick SC, Bunner P, Leadmon S, Elder P, Hofmeister C, Penza S, Efebera Y, Andritsos L, Garzon R, Benson DM Jr, Blum W, Devine S (2011). Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan-based reduced toxicity conditioning. Hematological oncology, 29(4), 202-10. (Read full publication)
29. Havelange V, Stauffer N, Heaphy CC, Volinia S, Andreeff M, Marcucci G, Croce CM, Garzon (2011). Functional implications of microRNAs in acute myeloid leukemia by integrating microRNA and messenger RNA expression profiling. Cancer, 117(20), 4696-706. (Read full publication)
30. Ranganathan P, Heaphy CE, Costinean S, Stauffer N, Na C, Hamadani M, Santhanam R, Mao C, Taylor PA, Sandhu S, He G, Shana'ah A, Nuovo GJ, Lagana A, Cascione L, Obad S, Broom O, Kauppinen S, Byrd JC, Caligiuri M, Perrotti D, Hadley GA, Marcucci G, Devine SM, Blazar BR, Croce CM, Garzon (2012). Regulation of acute graft-versus-host disease by microRNA-155. Blood, 119(20), 4786-97. (Read full publication)
31. Blum W, Schwind S, Tarighat SS, Geyer S, Eisfeld AK, Whitman S, Walker A, Klisovic R, Byrd JC, Santhanam R, Wang H, Curfman JP, Devine SM, Jacob S, Garr C, Kefauver C, Perrotti D, Chan KK, Bloomfield CD, Caligiuri MA, Grever MR, Garzon R, Marcucci (2012). Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia. Blood, 119(25), 6025-31. (Read full publication)
32. Wang H, Chiu M, Xie Z, Chiu M, Liu Z, Chen P, Liu S, Byrd JC, Muthusamy N, Garzon R, Croce CM, Marcucci G, Chan K (2012). Synthetic microRNA cassette dosing: pharmacokinetics, tissue distribution and bioactivity. Molecular pharmaceutics, 9(6), 1638-44. (Read full publication)
33. Ranganathan P, Yu X, Na C, Santhanam R, Shacham S, Kauffman M, Walker A, Klisovic R, Blum W, Caligiuri M, Croce CM, Marcucci G, Garzon (2012). Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia. Blood, 120(9), 1765-73. (Read full publication)
34. Yan P, Frankhouser D, Murphy M, Tam HH, Rodriguez B, Curfman J, Trimarchi M, Geyer S, Wu YZ, Whitman SP, Metzeler K, Walker A, Klisovic R, Jacob S, Grever MR, Byrd JC, Bloomfield CD, Garzon R, Blum W, Caligiuri MA, Bundschuh R, Marcucci (2012). Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia. Blood, 120(12), 2466-74. (Read full publication)
35. Baden LR, Bensinger W, Angarone M, Casper C, Dubberke ER, Freifeld AG, Garzon R, Greene JN, Greer JP, Ito JI, Karp JE, Kaul DR, King E, Mackler E, Marr KA, Montoya JG, Morris-Engemann A, Pappas PG, Rolston K, Segal B, Seo SK, Swaminathan S, Naganuma M, Shead DA, National Comprehensive Cancer Network (2012). Prevention and treatment of cancer-related infections. Journal of the National Comprehensive Cancer Network, 10(11), 1412-45. (Read full publication)
36. Hickey CJ, Schwind S, Radomska HS, Dorrance AM, Santhanam R, Mishra A, Wu YZ, Alachkar H, Maharry K, Nicolet D, Mrózek K, Walker A, Eiring AM, Whitman SP, Becker H, Perrotti D, Wu LC, Zhao X, Fehniger TA, Vij R, Byrd JC, Blum W, Lee LJ, Caligiuri MA, Bloomfield CD, Garzon R, Marcucci (2013). Lenalidomide-mediated enhanced translation of C/EBP¿-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia. Blood, 121(1), 159-69. (Read full publication)
37. Mishra A, Liu S, Sams GH, Curphey DP, Santhanam R, Rush LJ, Schaefer D, Falkenberg LG, Sullivan L, Jaroncyk L, Yang X, Fisk H, Wu LC, Hickey C, Chandler JC, Wu YZ, Heerema NA, Chan KK, Perrotti D, Zhang J, Porcu P, Racke FK, Garzon R, Lee RJ, Marcucci G, Caligiuri M (2012). Aberrant overexpression of IL-15 initiates large granular lymphocyte leukemia through chromosomal instability and DNA hypermethylation. Cancer cell, 22(5), 645-55. (Read full publication)
38. Sandhu SK, Volinia S, Costinean S, Galasso M, Neinast R, Santhanam R, Parthun MR, Perrotti D, Marcucci G, Garzon R, Croce C (2012). miR-155 targets histone deacetylase 4 (HDAC4) and impairs transcriptional activity of B-cell lymphoma 6 (BCL6) in the E¿-miR-155 transgenic mouse model. Proceedings of the National Academy of Sciences of the United States of America, 109(49), 20047-52. (Read full publication)
39. Mims A, Walker AR, Huang X, Sun J, Wang H, Santhanam R, Dorrance AM, Walker C, Hoellerbauer P, Tarighat SS, Chan KK, Klisovic RB, Perrotti D, Caligiuri MA, Byrd JC, Chen CS, James Lee L, Jacob S, Mrózek K, Bloomfield CD, Blum W, Garzon R, Schwind S, Marcucci (2013). Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia. Leukemia, 27(4), 871-8. (Read full publication)
40. Wang H, Chen P, Wang J, Santhanam R, Aimiuwu J, Saradhi UV, Liu Z, Schwind S, Mims A, Byrd JC, Grever MR, Villalona-Calero MA, Klisovic R, Walker A, Garzon R, Blum W, Chan KK, Marcucci (2013). In vivo quantification of active decitabine-triphosphate metabolite: a novel pharmacoanalytical endpoint for optimization of hypomethylating therapy in acute myeloid leukemia. The AAPS journal, 15(1), 242-9. (Read full publication)
41. Walker AR, Klisovic R, Johnston JS, Jiang Y, Geyer S, Kefauver C, Binkley P, Byrd JC, Grever MR, Garzon R, Phelps MA, Marcucci G, Blum KA, Blum (2013). Pharmacokinetics and dose escalation of the heat shock protein inhibitor 17-allyamino-17-demethoxygeldanamycin in combination with bortezomib in relapsed or refractory acute myeloid leukemia. Leukemia & lymphoma, 54(9), 1996-2002. (Read full publication)
42. Phillips CL, Davies SM, McMasters R, Absalon M, O'Brien M, Mo J, Broun R, Moscow JA, Smolarek T, Garzon R, Blum W, Schwind S, Marcucci G, Perentesis J (2013). Low dose decitabine in very high risk relapsed or refractory acute myeloid leukaemia in children and young adults. British journal of haematology, 161(3), 406-10. (Read full publication)
43. Huang X, Schwind S, Yu B, Santhanam R, Wang H, Hoellerbauer P, Mims A, Klisovic R, Walker AR, Chan KK, Blum W, Perrotti D, Byrd JC, Bloomfield CD, Caligiuri MA, Lee RJ, Garzon R, Muthusamy N, Lee LJ, Marcucci (2013). Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia. Clinical cancer research, 19(9), 2355-67. (Read full publication)
44. Alachkar H, Santhanam R, Harb JG, Lucas DM, Oaks JJ, Hickey CJ, Pan L, Kinghorn AD, Caligiuri MA, Perrotti D, Byrd JC, Garzon R, Grever MR, Marcucci (2013). Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia. Journal of hematology & oncology, 6, 21. (Read full publication)
45. Marcucci G, Maharry KS, Metzeler KH, Volinia S, Wu YZ, Mrózek K, Nicolet D, Kohlschmidt J, Whitman SP, Mendler JH, Schwind S, Becker H, Eisfeld AK, Carroll AJ, Powell BL, Kolitz JE, Garzon R, Caligiuri MA, Stone RM, Bloomfield C (2013). Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients. Journal of clinical oncology, 31(17), 2086-93. (Read full publication)
46. Chen Y, Jacamo R, Konopleva M, Garzon R, Croce C, Andreeff (2013). CXCR4 downregulation of let-7a drives chemoresistance in acute myeloid leukemia. The Journal of clinical investigation, 123(6), 2395-407. (Read full publication)
47. Walker CJ, Oaks JJ, Santhanam R, Neviani P, Harb JG, Ferenchak G, Ellis JJ, Landesman Y, Eisfeld AK, Gabrail NY, Smith CL, Caligiuri MA, Hokland P, Roy DC, Reid A, Milojkovic D, Goldman JM, Apperley J, Garzon R, Marcucci G, Shacham S, Kauffman MG, Perrotti (2013). Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias. Blood, 122(17), 3034-44. (Read full publication)
48. Neviani P, Harb JG, Oaks JJ, Santhanam R, Walker CJ, Ellis JJ, Ferenchak G, Dorrance AM, Paisie CA, Eiring AM, Ma Y, Mao HC, Zhang B, Wunderlich M, May PC, Sun C, Saddoughi SA, Bielawski J, Blum W, Klisovic RB, Solt JA, Byrd JC, Volinia S, Cortes J, Huettner CS, Koschmieder S, Holyoake TL, Devine S, Caligiuri MA, Croce CM, Garzon R, Ogretmen B, Arlinghaus RB, Chen CS, Bittman R, Hokland P, Roy DC, Milojkovic D, Apperley J, Goldman JM, Reid A, Mulloy JC, Bhatia R, Marcucci G, Perrotti (2013). PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. The Journal of clinical investigation, 123(10), 4144-57. (Read full publication)
49. Marcucci G, Yan P, Maharry K, Frankhouser D, Nicolet D, Metzeler KH, Kohlschmidt J, Mrózek K, Wu YZ, Bucci D, Curfman JP, Whitman SP, Eisfeld AK, Mendler JH, Schwind S, Becker H, Bär C, Carroll AJ, Baer MR, Wetzler M, Carter TH, Powell BL, Kolitz JE, Byrd JC, Plass C, Garzon R, Caligiuri MA, Stone RM, Volinia S, Bundschuh R, Bloomfield C (2014). Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score. Journal of clinical oncology, 32(6), 548-56. (Read full publication)
50. Alachkar H, Santhanam R, Maharry K, Metzeler KH, Huang X, Kohlschmidt J, Mendler JH, Benito JM, Hickey C, Neviani P, Dorrance AM, Anghelina M, Khalife J, Tarighat SS, Volinia S, Whitman SP, Paschka P, Hoellerbauer P, Wu YZ, Han L, Bolon BN, Blum W, Mrózek K, Carroll AJ, Perrotti D, Andreeff M, Caligiuri MA, Konopleva M, Garzon R, Bloomfield CD, Marcucci (2014). SPARC promotes leukemic cell growth and predicts acute myeloid leukemia outcome. The Journal of clinical investigation, 124(4), 1512-24. (Read full publication)
51. Havelange V, Ranganathan P, Geyer S, Nicolet D, Huang X, Yu X, Volinia S, Kornblau SM, Andreeff M, Croce CM, Marcucci G, Bloomfield CD, Garzon (2014). Implications of the miR-10 family in chemotherapy response of NPM1-mutated AML. Blood, 123(15), 2412-5. (Read full publication)
52. Walker AR, Klisovic RB, Garzon R, Schaaf LJ, Humphries K, Devine SM, Byrd JC, Grever MR, Marcucci G, Blum (2014). Phase I study of azacitidine and bortezomib in adults with relapsed or refractory acute myeloid leukemia. Leukemia & lymphoma, 55(6), 1304-8. (Read full publication)
53. Galasso M, Dama P, Previati M, Sandhu S, Palatini J, Coppola V, Warner S, Sana ME, Zanella R, Abujarour R, Desponts C, Teitell MA, Garzon R, Calin G, Croce CM, Volinia (2014). A large scale expression study associates uc.283-plus lncRNA with pluripotent stem cells and human glioma. Genome medicine, 6(10), 76. (Read full publication)
54. Volinia S, Nuovo G, Drusco A, Costinean S, Abujarour R, Desponts C, Garofalo M, Baffa R, Aeqilan R, Maharry K, Sana ME, Di Leva G, Gasparini P, Dama P, Marchesini J, Galasso M, Manfrini M, Zerbinati C, Corrà F, Wise T, Wojcik SE, Previati M, Pichiorri F, Zanesi N, Alder H, Palatini J, Huebner KF, Shapiro CL, Negrini M, Vecchione A, Rosenberg AL, Croce CM, Garzon (2014). Pluripotent stem cell miRNAs and metastasis in invasive breast cancer. Journal of the National Cancer Institute, 106(12), (Read full publication)
55. Garzon R, Volinia S, Papaioannou D, Nicolet D, Kohlschmidt J, Yan PS, Mrózek K, Bucci D, Carroll AJ, Baer MR, Wetzler M, Carter TH, Powell BL, Kolitz JE, Moore JO, Eisfeld AK, Blachly JS, Blum W, Caligiuri MA, Stone RM, Marcucci G, Croce CM, Byrd JC, Bloomfield C (2014). Expression and prognostic impact of lncRNAs in acute myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America, 111(52), 18679-84. (Read full publication)
56. Ranganathan P, Yu X, Santhanam R, Hofstetter J, Walker A, Walsh K, Bhatnagar B, Klisovic R, Vasu S, Phelps MA, Devine S, Shacham S, Kauffman M, Marcucci G, Blum W, Garzon (2015). Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia. Blood, 125(17), 2689-92. (Read full publication)
57. Khalife J, Radomska HS, Santhanam R, Huang X, Neviani P, Saultz J, Wang H, Wu YZ, Alachkar H, Anghelina M, Dorrance A, Curfman J, Bloomfield CD, Medeiros BC, Perrotti D, Lee LJ, Lee RJ, Caligiuri MA, Pichiorri F, Croce CM, Garzon R, Guzman ML, Mendler JH, Marcucci (2015). Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia. Leukemia, 29(10), 1981-92. (Read full publication)
58. Dorrance AM, Neviani P, Ferenchak GJ, Huang X, Nicolet D, Maharry KS, Ozer HG, Hoellarbauer P, Khalife J, Hill EB, Yadav M, Bolon BN, Lee RJ, Lee LJ, Croce CM, Garzon R, Caligiuri MA, Bloomfield CD, Marcucci (2015). Targeting leukemia stem cells in vivo with antagomiR-126 nanoparticles in acute myeloid leukemia. Leukemia, 29(11), 2143-53. (Read full publication)
59. Efebera YA, Geyer S, Andritsos L, Vasu S, Jaglowski S, Bingman A, Blum W, Klisovic R, Hofmeister CC, Benson DM, Penza S, Elder P, Cortright K, Kitzler R, Coombes K, O'Donnell L, Daneault B, Bradbury H, Zhang J, Chen X, Garman S, Ranganathan P, Yu X, Hofstetter J, Yu J, Garzon R, Scrape SR, Lozanski G, Devine S (2016). Atorvastatin for the Prophylaxis of Acute Graft-versus-Host Disease in Patients Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT). Biology of blood and marrow transplantation, 22(1), 71-9. (Read full publication)
60. Tarighat SS, Santhanam R, Frankhouser D, Radomska HS, Lai H, Anghelina M, Wang H, Huang X, Alinari L, Walker A, Caligiuri MA, Croce CM, Li L, Garzon R, Li C, Baiocchi RA, Marcucci (2016). The dual epigenetic role of PRMT5 in acute myeloid leukemia: gene activation and repression via histone arginine methylation. Leukemia, 30(4), 789-99. (Read full publication)
61. Walker AR, Wang H, Walsh K, Bhatnagar B, Vasu S, Garzon R, Canning R, Geyer S, Wu YZ, Devine SM, Klisovic R, Blum W, Marcucci (2016). Midostaurin, bortezomib and MEC in relapsed/refractory acute myeloid leukemia. Leukemia & lymphoma, 57(9), 2100-8. (Read full publication)
62. Lai TH, Ewald B, Zecevic A, Liu C, Sulda M, Papaioannou D, Garzon R, Blachly JS, Plunkett W, Sampath (2016). HDAC Inhibition Induces MicroRNA-182, which Targets RAD51 and Impairs HR Repair to Sensitize Cells to Sapacitabine in Acute Myelogenous Leukemia. Clinical cancer research, 22(14), 3537-49. (Read full publication)
63. Cheng H, Xie Z, Jones WP, Wei XT, Liu Z, Wang D, Kulp SK, Wang J, Coss CC, Chen CS, Marcucci G, Garzon R, Covey JM, Phelps MA, Chan K (2016). Preclinical Pharmacokinetics Study of R- and S-Enantiomers of the Histone Deacetylase Inhibitor, AR-42 (NSC 731438), in Rodents. The AAPS journal, 18(3), 737-45. (Read full publication)
64. Ranganathan P, Kashyap T, Yu X, Meng X, Lai TH, McNeil B, Bhatnagar B, Shacham S, Kauffman M, Dorrance AM, Blum W, Sampath D, Landesman Y, Garzon (2016). XPO1 Inhibition using Selinexor Synergizes with Chemotherapy in Acute Myeloid Leukemia by Targeting DNA Repair and Restoring Topoisomerase II¿ to the Nucleus. Clinical cancer research, 22(24), 6142-6152. (Read full publication)
65. Maharry SE, Walker CJ, Liyanarachchi S, Mehta S, Patel M, Bainazar MA, Huang X, Lankenau MA, Hoag KW, Ranganathan P, Garzon R, Blachly JS, Guttridge DC, Bloomfield CD, de la Chapelle A, Eisfeld A (2016). Dissection of the Major Hematopoietic Quantitative Trait Locus in Chromosome 6q23.3 Identifies miR-3662 as a Player in Hematopoiesis and Acute Myeloid Leukemia. Cancer discovery, 6(9), 1036-51. (Read full publication)
66. Hing ZA, Fung HY, Ranganathan P, Mitchell S, El-Gamal D, Woyach JA, Williams K, Goettl VM, Smith J, Yu X, Meng X, Sun Q, Cagatay T, Lehman AM, Lucas DM, Baloglu E, Shacham S, Kauffman MG, Byrd JC, Chook YM, Garzon R, Lapalombella (2016). Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignancies. Leukemia, 30(12), 2364-2372. (Read full publication)
67. Lu Y, Hippen KL, Lemire AL, Gu J, Wang W, Ni X, Ranganathan P, Levine BL, Riley JL, June CH, Turka LA, Munn DH, Garzon R, Lu L, Blazar B (2016). miR-146b antagomir-treated human Tregs acquire increased GVHD inhibitory potency. Blood, 128(10), 1424-35. (Read full publication)
68. Ranganathan P, Ngankeu A, Zitzer NC, Leoncini P, Yu X, Casadei L, Challagundla K, Reichenbach DK, Garman S, Ruppert AS, Volinia S, Hofstetter J, Efebera YA, Devine SM, Blazar BR, Fabbri M, Garzon (2017). Serum miR-29a Is Upregulated in Acute Graft-versus-Host Disease and Activates Dendritic Cells through TLR Binding. Journal of immunology (Baltimore, Md., 198(6), 2500-2512. (Read full publication)
69. Garzon R, Savona M, Baz R, Andreeff M, Gabrail N, Gutierrez M, Savoie L, Mau-Sorensen PM, Wagner-Johnston N, Yee K, Unger TJ, Saint-Martin JR, Carlson R, Rashal T, Kashyap T, Klebanov B, Shacham S, Kauffman M, Stone (2017). A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia. Blood, 129(24), 3165-3174. (Read full publication)
70. Papaioannou D, Nicolet D, Volinia S, Mrózek K, Yan P, Bundschuh R, Carroll AJ, Kohlschmidt J, Blum W, Powell BL, Uy GL, Kolitz JE, Wang ES, Eisfeld AK, Orwick SJ, Lucas DM, Caligiuri MA, Stone RM, Byrd JC, Garzon R, Bloomfield C (2017). Prognostic and biologic significance of long non-coding RNA profiling in younger adults with cytogenetically normal acute myeloid leukemia. Haematologica, 102(8), 1391-1400. (Read full publication)
71. Kuruvilla J, Savona M, Baz R, Mau-Sorensen PM, Gabrail N, Garzon R, Stone R, Wang M, Savoie L, Martin P, Flinn I, Jacoby M, Unger TJ, Saint-Martin JR, Rashal T, Friedlander S, Carlson R, Kauffman M, Shacham S, Gutierrez (2017). Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma. Blood, 129(24), 3175-3183. (Read full publication)
72. He Z, Hu X, Liu W, Dorrance A, Garzon R, Houghton PJ, Shen (2017). P53 suppresses ribonucleotide reductase via inhibiting mTORC1. Oncotarget, 8(25), 41422-41431. (Read full publication)
73. Zhou X, Liu W, Hu X, Dorrance A, Garzon R, Houghton PJ, Shen (2017). Regulation of CHK1 by mTOR contributes to the evasion of DNA damage barrier of cancer cells. Scientific reports, 7(1), 1535. (Read full publication)
74. Papaioannou D, Shen C, Nicolet D, McNeil B, Bill M, Karunasiri M, Burke MH, Ozer HG, Yilmaz SA, Zitzer N, Behbehani GK, Oakes CC, Steiner DJ, Marcucci G, Powell BL, Kolitz JE, Carter TH, Wang ES, Mrózek K, Croce CM, Caligiuri MA, Bloomfield CD, Garzon R, Dorrance A (2017). Prognostic and biological significance of the proangiogenic factor EGFL7 in acute myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America, 114(23), E4641-E4647. (Read full publication)
75. Ngankeu A, Ranganathan P, Havelange V, Nicolet D, Volinia S, Powell BL, Kolitz JE, Uy GL, Stone RM, Kornblau SM, Andreeff M, Croce CM, Bloomfield CD, Garzon (2017). Discovery and functional implications of a miR-29b-1/miR-29a cluster polymorphism in acute myeloid leukemia. Oncotarget, 9(4), 4354-4365. (Read full publication)
76. Di Marcantonio D, Martinez E, Sidoli S, Vadaketh J, Nieborowska-Skorska M, Gupta A, Meadows JM, Ferraro F, Masselli E, Challen GA, Milsom MD, Scholl C, Fröhling S, Balachandran S, Skorski T, Garcia BA, Mirandola P, Gobbi G, Garzon R, Vitale M, Sykes S (2018). Protein Kinase C Epsilon Is a Key Regulator of Mitochondrial Redox Homeostasis in Acute Myeloid Leukemia. Clinical cancer research, 24(3), 608-618. (Read full publication)
77. Zitzer NC, Snyder K, Meng X, Taylor PA, Efebera YA, Devine SM, Blazar BR, Garzon R, Ranganathan (2018). MicroRNA-155 Modulates Acute Graft-versus-Host Disease by Impacting T Cell Expansion, Migration, and Effector Function. Journal of immunology (Baltimore, Md., 200(12), 4170-4179. (Read full publication)
78. Mims AS, Mishra A, Orwick S, Blachly J, Klisovic RB, Garzon R, Walker AR, Devine SM, Walsh KJ, Vasu S, Whitman S, Marcucci G, Jones D, Heerema NA, Lozanski G, Caligiuri MA, Bloomfield CD, Byrd JC, Piekarz R, Grever MR, Blum (2018). A novel regimen for relapsed/refractory adult acute myeloid leukemia using a KMT2A partial tandem duplication targeted therapy: results of phase 1 study NCI 8485. Haematologica, 103(6), 982-987. (Read full publication)
79. Lovat F, Fassan M, Sacchi D, Ranganathan P, Palamarchuk A, Bill M, Karunasiri M, Gasparini P, Nigita G, Distefano R, Veneziano D, Dorrance AM, Garzon R, Croce C (2018). Knockout of both miR-15/16 loci induces acute myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America, 115(51), 13069-13074. (Read full publication)
80. Papaioannou D, Nicolet D, Ozer HG, Mrózek K, Volinia S, Fadda P, Carroll AJ, Kohlschmidt J, Kolitz JE, Wang ES, Stone RM, Byrd JC, Garzon R, Bloomfield C (2019). Prognostic and Biologic Relevance of Clinically Applicable Long Noncoding RNA Profiling in Older Patients with Cytogenetically Normal Acute Myeloid Leukemia. Molecular cancer therapeutics, 18(8), 1451-1459. (Read full publication)
81. Efebera YA, Ruppert AS, Ngankeu A, Garman S, Kumchala P, Howard A, Devine SM, Ranganathan P, Garzon (2019). Serum MicroRNA-155 in Acute Graft-Versus-Host-Disease (aGVHD). 2, 079-82. (Read full publication)
82. Bill M, Papaioannou D, Karunasiri M, Kohlschmidt J, Pepe F, Walker CJ, Walker AE, Brannan Z, Pathmanathan A, Zhang X, Mrózek K, LaRocco A, Volinia S, Bloomfield CD, Garzon R, Dorrance A (2019). Expression and functional relevance of long non-coding RNAs in acute myeloid leukemia stem cells. Leukemia, 33(9), 2169-2182. (Read full publication)
83. Papaioannou D, Petri A, Dovey OM, Terreri S, Wang E, Collins FA, Woodward LA, Walker AE, Nicolet D, Pepe F, Kumchala P, Bill M, Walker CJ, Karunasiri M, Mrózek K, Gardner ML, Camilotto V, Zitzer N, Cooper JL, Cai X, Rong-Mullins X, Kohlschmidt J, Archer KJ, Freitas MA, Zheng Y, Lee RJ, Aifantis I, Vassiliou G, Singh G, Kauppinen S, Bloomfield CD, Dorrance AM, Garzon (2019). The long non-coding RNA HOXB-AS3 regulates ribosomal RNA transcription in NPM1-mutated acute myeloid leukemia. Nature communications, 10(1), 5351. (Read full publication)
84. Jeon JY, Zhao Q, Buelow DR, Phelps M, Walker AR, Mims AS, Vasu S, Behbehani G, Blachly J, Blum W, Klisovic RB, Byrd JC, Garzon R, Baker SD, Bhatnagar (2020). Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML. Investigational new drugs, 38(2), 340-349. (Read full publication)
85. Bhatnagar B, Zhao Q, Mims AS, Vasu S, Behbehani GK, Larkin K, Blachly JS, Blum W, Klisovic RB, Ruppert AS, Orwick S, Oakes C, Ranganathan P, Byrd JC, Walker AR, Garzon (2020). Selinexor in combination with decitabine in patients with acute myeloid leukemia: results from a phase 1 study. Leukemia & lymphoma, 61(2), 387-396. (Read full publication)
86. Bill M, Nicolet D, Kohlschmidt J, Walker CJ, Mrózek K, Eisfeld AK, Papaioannou D, Rong-Mullins X, Brannan Z, Kolitz JE, Powell BL, Archer KJ, Dorrance AM, Carroll AJ, Stone RM, Byrd JC, Garzon R, Bloomfield C (2020). Mutations associated with a 17-gene leukemia stem cell score and the score's prognostic relevance in the context of the European Leukemia Net classification of acute myeloid leukemia. Haematologica, 105(3), 721-729. (Read full publication)
87. Bill M, Pathmanathan A, Karunasiri M, Shen C, Burke MH, Ranganathan P, Papaioannou D, Zitzer NC, Snyder K, LaRocco A, Walker AE, Brannan ZJ, Nalin AP, Freud AG, Dikov MM, Zhang X, Bloomfield CD, Garzon R, Dorrance A (2020). EGFL7 Antagonizes NOTCH Signaling and Represents a Novel Therapeutic Target in Acute Myeloid Leukemia. Clinical cancer research, 26(3), 669-678. (Read full publication)
88. Papaioannou D, Volinia S, Nicolet D, ¿wierniak M, Petri A, Mrózek K, Bill M, Pepe F, Walker CJ, Walker AE, Carroll AJ, Kohlschmidt J, Eisfeld AK, Powell BL, Uy GL, Kolitz JE, Wang ES, Kauppinen S, Dorrance A, Stone RM, Byrd JC, Bloomfield CD, Garzon (2020). Clinical and functional significance of circular RNAs in cytogenetically normal AML. Blood advances, 4(2), 239-251. (Read full publication)
89. Snyder KJ, Zitzer NC, Gao Y, Choe HK, Sell NE, Neidemire-Colley L, Ignaci A, Kale C, Devine RD, Abad MG, Pietrzak M, Wang M, Lin H, Zhang YW, Behbehani GK, Jackman JE, Garzon R, Vaddi K, Baiocchi RA, Ranganathan (2020). PRMT5 regulates T cell interferon response and is a target for acute graft-versus-host disease. JCI insight, 5(8), (Read full publication)
90. Liva SG, Coss CC, Wang J, Blum W, Klisovic R, Bhatnagar B, Walsh K, Geyer S, Zhao Q, Garzon R, Marcucci G, Phelps MA, Walker A (2020). Phase I study of AR-42 and decitabine in acute myeloid leukemia. Leukemia & lymphoma, 61(6), 1484-1492. (Read full publication)
91. Saygin C, Larkin K, Blachly JS, Orwick S, Ngankeu A, Gregory CT, Phelps MA, Mani S, Walker A, Garzon R, Vasu S, Walsh KJ, Bhatnagar B, Klisovic RB, Grever MR, Marcucci G, Byrd JC, Blum W, Mims A (2020). A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. American journal of hematology, 95(12), 1457-1465. (Read full publication)
92. Silvestri G, Trotta R, Stramucci L, Ellis JJ, Harb JG, Neviani P, Wang S, Eisfeld AK, Walker CJ, Zhang B, Srutova K, Gambacorti-Passerini C, Pineda G, Jamieson CHM, Stagno F, Vigneri P, Nteliopoulos G, May PC, Reid AG, Garzon R, Roy DC, Moutuou MM, Guimond M, Hokland P, Deininger MW, Fitzgerald G, Harman C, Dazzi F, Milojkovic D, Apperley JF, Marcucci G, Qi J, Polakova KM, Zou Y, Fan X, Baer MR, Calabretta B, Perrotti (2020). Persistence of Drug-Resistant Leukemic Stem Cells and Impaired NK Cell Immunity in CML Patients Depend on MIR300 Antiproliferative and PP2A-Activating Functions. Blood cancer discovery, 1(1), 48-67. (Read full publication)
93. Underwood B, Zhao Q, Walker AR, Mims AS, Vasu S, Long M, Z Haque T, Blaser BW, Grieselhuber NR, Wall SA, Behbehani GK, Blachly JS, Larkin K, Byrd JC, Garzon R, Wang TF, Bhatnagar (2020). Incidence of venous thrombosis after peg-asparaginase in adolescent and young adults with acute lymphoblastic leukemia. International journal of hematologic oncology, 9(3), IJH28. (Read full publication)
94. Bhatnagar B, Kohlschmidt J, Mrózek K, Zhao Q, Fisher JL, Nicolet D, Walker CJ, Mims AS, Oakes C, Giacopelli B, Orwick S, Boateng I, Blachly JS, Maharry SE, Carroll AJ, Powell BL, Kolitz JE, Stone RM, Byrd JC, Paskett ED, de la Chapelle A, Garzon R, Eisfeld A (2021). Poor Survival and Differential Impact of Genetic Features of Black Patients with Acute Myeloid Leukemia. Cancer discovery, 11(3), 626-637. (Read full publication)
95. Walker CJ, Mrózek K, Ozer HG, Nicolet D, Kohlschmidt J, Papaioannou D, Genutis LK, Bill M, Powell BL, Uy GL, Kolitz JE, Carroll AJ, Stone RM, Garzon R, Byrd JC, Eisfeld AK, de la Chapelle A, Bloomfield C (2021). Gene expression signature predicts relapse in adult patients with cytogenetically normal acute myeloid leukemia. Blood advances, 5(5), 1474-1482. (Read full publication)
96. Di Marcantonio D, Martinez E, Kanefsky JS, Huhn JM, Gabbasov R, Gupta A, Krais JJ, Peri S, Tan Y, Skorski T, Dorrance A, Garzon R, Goldman AR, Tang HY, Johnson N, Sykes S (2021). ATF3 coordinates serine and nucleotide metabolism to drive cell cycle progression in acute myeloid leukemia. Molecular cell, 81(13), 2752-2764.e6. (Read full publication)
97. Pepe F, Bill M, Papaioannou D, Karunasiri M, Walker A, Naumann E, Snyder K, Ranganathan P, Dorrance A, Garzon (2022). Targeting Wnt signaling in acute myeloid leukemia stem cells. Haematologica, 107(1), 307-311. (Read full publication)
98. Giacopelli B, Wang M, Cleary A, Wu YZ, Schultz AR, Schmutz M, Blachly JS, Eisfeld AK, Mundy-Bosse B, Vosberg S, Greif PA, Claus R, Bullinger L, Garzon R, Coombes KR, Bloomfield CD, Druker BJ, Tyner JW, Byrd JC, Oakes C (2021). DNA methylation epitypes highlight underlying developmental and disease pathways in acute myeloid leukemia. Genome research, 31(5), 747-761. (Read full publication)
99. Fobare S, Kohlschmidt J, Ozer HG, Mrózek K, Nicolet D, Mims AS, Garzon R, Blachly JS, Orwick S, Carroll AJ, Stone RM, Wang ES, Kolitz JE, Powell BL, Oakes CC, Eisfeld AK, Hertlein E, Byrd J (2022). Molecular, clinical, and prognostic implications of PTPN11 mutations in acute myeloid leukemia. Blood advances, 6(5), 1371-1380. (Read full publication)
100. Dorrance AM, Moutuou MM, Goda C, Sell NE, Kalyan S, Karunasiri M, Kulkarni R, Goulard M, Kolovich S, Rudich A, Naumann E, Ackaoui A, Bigras CE, Daudelin F, Garzon R, Ranganathan P, Guimond (2022). Modulating endothelial cells with EGFL7 to diminish aGVHD after allogeneic bone marrow transplantation in mice. Blood advances, 6(7), 2403-2408. (Read full publication)
101. Papaioannou D, Ozer HG, Nicolet D, Urs AP, Herold T, Mrózek K, Batcha AMN, Metzeler KH, Yilmaz AS, Volinia S, Bill M, Kohlschmidt J, Pietrzak M, Walker CJ, Carroll AJ, Braess J, Powell BL, Eisfeld AK, Uy GL, Wang ES, Kolitz JE, Stone RM, Hiddemann W, Byrd JC, Bloomfield CD, Garzon (2022). Clinical and molecular relevance of genetic variants in the non-coding transcriptome of patients with cytogenetically normal acute myeloid leukemia. Haematologica, 107(5), 1034-1044. (Read full publication)
102. Kuo CT, Lee RJ, Garzon (2021). Methods Used to Make Lipid Nanoparticles to Deliver LNA Gapmers Against lncRNAs into Acute Myeloid Leukemia (AML) Blasts. Methods in molecular biology (Clifton, N.J.), 2348, 167-174. (Read full publication)
103. Kuo CT, Lee RJ, Garzon (2021). Correction to: Methods Used to Make Lipid Nanoparticles to Deliver LNA Gapmers Against lncRNAs into Acute Myeloid Leukemia (AML) Blasts. Methods in molecular biology (Clifton, N.J.), 2348, C1. (Read full publication)
104. Leoncini PP, Bertaina A, Papaioannou D, Flotho C, Masetti R, Bresolin S, Menna G, Santoro N, Zecca M, Basso G, Nigita G, Veneziano D, Pagotto S, D'Ovidio K, Rota R, Dorrance A, Croce CM, Niemeyer C, Locatelli F, Garzon (2016). MicroRNA fingerprints in juvenile myelomonocytic leukemia (JMML) identified miR-150-5p as a tumor suppressor and potential target for treatment. Oncotarget, 7(34), 55395-55408. (Read full publication)
105. Mishra A, Garzon (2014). The (miR)e of CTCL. Blood, 123(10), 1438. (Read full publication)
106. Bhatnagar B, Garzon (2016). Long noncoding RNAs to predict survival in acute myeloid leukemia: a step toward personalized medicine?. Biomarkers in medicine, 10(9), 935-8. (Read full publication)
107. Bill M, Nicolet D, Kohlschmidt J, Walker CJ, Mrózek K, Eisfeld AK, Papaioannou D, Rong-Mullins X, Brannan Z, Kolitz JE, Powell BL, Archer KJ, Dorrance AM, Carroll AJ, Stone RM, Byrd JC, Garzon R, Bloomfield C (2020). Mutations associated with a 17-gene leukemia stem cell score and the score's prognostic relevance in the context of the European Leukemia Net classification of acute myeloid leukemia. Haematologica, 105(3), 721-9.
108. Goda C, Kolovich S, Rudich A, Karunasiri M, Kulkarni R, Rajgolikar G, Neidemire-Colley L, Singh S, Sircar A, Ranganathan P, Garzon R, Sehgal L, Dorrance A (2023). Epidermal growth factor-like 7 is a novel therapeutic target in mantle cell lymphoma. Experimental hematology, 123, 28-33.e3. (Read full publication)
109. Crudele F, Bianchi N, Terrazzan A, Ancona P, Frassoldati A, Gasparini P, D'Adamo AP, Papaioannou D, Garzon R, Wójcicka A, Gaj P, Ja'd¿ewski K, Palatini J, Volinia (2023). Circular RNAs Could Encode Unique Proteins and Affect Cancer Pathways. Biology, 12(4), (Read full publication)
110. Goda C, Kulkarni R, Bustos Y, Li W, Rudich A, Balcioglu O, Chidester S, Urs AP, Karunasiri M, Al-Marrawi Y, Korn E, Kanna S, Garfinkle EAR, Shah N, Wooten A, Mundy-Bosse B, Sehgal L, Zhang B, Marcucci G, Mardis ER, Garzon R, Bowman RL, Viny AD, Miles LA, Miller KE, Dorrance A (2024). Cellular taxonomy of the preleukemic bone marrow niche of acute myeloid leukemia. Leukemia, 39(1), 51-63. (Read full publication)
111. Neidemire-Colley L, Khanal S, Braunreiter KM, Gao Y, Kumar R, Snyder KJ, Weber MA, Surana S, Toirov O, Karunasiri M, Duszynski ME, Chi M, Malik P, Kalyan S, Chan WK, Naeimi Kararoudi M, Choe HK, Garzon R, Ranganathan (2024). CRISPR/Cas9 deletion of MIR155HG in human T cells reduces incidence and severity of acute GVHD in a xenogeneic model. Blood advances, 8(4), 947-958. (Read full publication)
112. Bhatnagar B, Zhao Q, Mims AS, Vasu S, Behbehani GK, Larkin K, Blachly JS, Badawi MA, Hill KL, Dzwigalski KR, Phelps MA, Blum W, Klisovic RB, Ruppert AS, Ranganathan P, Walker AR, Garzon (2023). Phase 1 study of selinexor in combination with salvage chemotherapy in Adults with relapsed or refractory Acute myeloid leukemia. Leukemia & lymphoma, 64(13), 2091-2100. (Read full publication)

Review

1. Robles AM, Casas JP, Pereyra MA, Garzón R, López A (2000). [Acute eosinophilic pneumonia. Case report and review of the literature]. Medicina, 60(5 Pt 1), 605-8. (Read full publication)
2. Erter J, Alinari L, Darabi K, Gurcan M, Garzon R, Marcucci G, Bechtel MA, Wong H, Porcu (2010). New targets of therapy in T-cell lymphomas. Current drug targets, 11(4), 482-93. (Read full publication)
3. Garzon R, Fabbri M, Cimmino A, Calin GA, Croce C (2006). MicroRNA expression and function in cancer. Trends in molecular medicine, 12(12), 580-7. (Read full publication)
4. Fabbri M, Garzon R, Andreeff M, Kantarjian HM, Garcia-Manero G, Calin G (2008). MicroRNAs and noncoding RNAs in hematological malignancies: molecular, clinical and therapeutic implications. Leukemia, 22(6), 1095-105. (Read full publication)
5. Garzon R, Croce C (2008). MicroRNAs in normal and malignant hematopoiesis. Current opinion in hematology, 15(4), 352-8. (Read full publication)
6. Garzon (2009). MicroRNA profiling of megakaryocytes. Methods in molecular biology (Clifton, N.J.), 496, 293-8. (Read full publication)
7. Havelange V, Garzon R, Croce C (2009). MicroRNAs: new players in acute myeloid leukaemia. British journal of cancer, 101(5), 743-8. (Read full publication)
8. Garzon R, Marcucci G, Croce C (2010). Targeting microRNAs in cancer: rationale, strategies and challenges. Nature reviews. Drug discovery, 9(10), 775-89. (Read full publication)
9. Havelange V, Garzon (2010). MicroRNAs: emerging key regulators of hematopoiesis. American journal of hematology, 85(12), 935-42. (Read full publication)
10. Sandhu S, Garzon (2011). Potential applications of microRNAs in cancer diagnosis, prognosis, and treatment. Seminars in oncology, 38(6), 781-7. (Read full publication)
11. Marcucci G, Mrózek K, Radmacher MD, Garzon R, Bloomfield C (2011). The prognostic and functional role of microRNAs in acute myeloid leukemia. Blood, 117(4), 1121-9. (Read full publication)
12. Garzon R, Marcucci (2012). Potential of microRNAs for cancer diagnostics, prognostication and therapy. Current opinion in oncology, 24(6), 655-9. (Read full publication)
13. Bhatnagar B, Garzon (2014). The use of molecular genetics to refine prognosis in acute myeloid leukemia. Current hematologic malignancy reports, 9(2), 148-57. (Read full publication)
14. Saultz JN, Garzon (2016). Acute Myeloid Leukemia: A Concise Review. Journal of clinical medicine, 5(3), (Read full publication)
15. Zitzer NC, Garzon R, Ranganathan (2018). Toll-Like Receptor Stimulation by MicroRNAs in Acute Graft-vs.-Host Disease. Frontiers in immunology, 9, 2561. (Read full publication)
16. Walker JS, Garzon R, Lapalombella (2020). Selinexor for advanced hematologic malignancies. Leukemia & lymphoma, 61(10), 2335-2350. (Read full publication)
17. Bhatnagar B, Garzon (2021). Clinical Applications of MicroRNAs in Acute Myeloid Leukemia: A Mini-Review. Frontiers in oncology, 11, 679022. (Read full publication)
18. Garzon R, Calin GA, Croce C (2009). MicroRNAs in Cancer. Annual review of medicine, 60, 167-79. (Read full publication)

Editorial

1. Calin GA, Garzon R, Cimmino A, Fabbri M, Croce C (2006). MicroRNAs and leukemias: how strong is the connection?. Leukemia research, 30(6), 653-5. (Read full publication)
2. Garzon R, Croce C (2011). MicroRNAs and cancer: introduction. Seminars in oncology, 38(6), 721-3. (Read full publication)

Letter

1. Metzeler KH, Walker A, Geyer S, Garzon R, Klisovic RB, Bloomfield CD, Blum W, Marcucci (2012). DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia. Leukemia, 26(5), 1106-7. (Read full publication)
2. Bill M, Goda C, Pepe F, Ozer HG, McNeil B, Zhang X, Karunasiri M, Kulkarni R, Kalyan S, Papaioannou D, Ferenchak G, Garzon R, Bradner JE, Marcucci G, Caligiuri MA, Dorrance A (2021). Targeting BRD4 in acute myeloid leukemia with partial tandem duplication of the MLL gene. Haematologica, 106(9), 2527-2532. (Read full publication)
3. Bill M, Mrózek K, Giacopelli B, Kohlschmidt J, Nicolet D, Papaioannou D, Eisfeld AK, Kolitz JE, Powell BL, Carroll AJ, Stone RM, Garzon R, Byrd JC, Bloomfield CD, Oakes C (2021). Precision oncology in AML: validation of the prognostic value of the knowledge bank approach and suggestions for improvement. Journal of hematology & oncology, 14(1), 107. (Read full publication)

Huntsman Cancer Institute News

• Ramiro Garzon, MD, to Lead Hematologic Cancers at Huntsman Cancer Institute and University of Utah Health